Medicare Enrolled
Dr. John Schwerkoske, MD
Hematology & Oncology · Chula Vista, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Schwerkoske from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Schwerkoske?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Schwerkoske
Dr. John Schwerkoske is a hematology & oncology specialist in Chula Vista, CA, with 13 years of NPI registration. Based on federal Medicare data, Dr. Schwerkoske performed 1,906 Medicare services across 257 unique beneficiaries.
Between the years covered by Open Payments, Dr. Schwerkoske received a total of $14,219 from 79 pharmaceutical and/or device companies across 521 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Schwerkoske is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice
▲ Top 41% volume in CA
$14,219 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,906
Medicare services
Top 41% in CA for hematology & oncology
257
Unique beneficiaries
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~147 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (ondansetron/Zofran) | 714 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
608 | $0 | $0 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
84 | $114 | $297 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
80 | $102 | $269 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
69 | $72 | $188 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
62 | $24 | $65 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
58 | $24 | $59 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
50 | $13 | $33 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
48 | $1 | $2 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
30 | $25 | $57 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
30 | $64 | $195 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
25 | $54 | $141 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
19 | $121 | $326 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
17 | $12 | $25 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
12 | $83 | $237 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.0% high complexity
78.4% medium
12.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,219
Total received (2018-2024)
Avg $2,031/year across 7 years
Top 27% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
79
Companies
521
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,287 (86.4%)
Other
Charitable contributions, space rental, and other categories
$1,052 (7.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$881 (6.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,264
2023
$5,052
2022
$3,651
2021
$647
2020
$118
2019
$121
2018
$367
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$877
AstraZeneca Pharmaceuticals LP
$329
Janssen Biotech, Inc.
$311
E.R. Squibb & Sons, L.L.C.
$308
Incyte Corporation
$284
Eisai Inc.
$219
Regeneron Healthcare Solutions, Inc.
$174
Daiichi Sankyo Inc.
$172
PFIZER INC.
$169
Celgene Corporation
$96
GlaxoSmithKline, LLC.
$94
Genentech USA, Inc.
$89
Dendreon Pharmaceuticals LLC
$81
Ipsen Biopharmaceuticals, Inc
$80
Takeda Pharmaceuticals U.S.A., Inc.
$78
Lilly USA, LLC
$72
ARRAY BIOPHARMA INC
$71
Alexion Pharmaceuticals, Inc.
$67
CSL Behring
$61
Tempus AI, Inc
$58
Pharmacosmos Therapeutics Inc.
$49
Agios Pharmaceuticals, Inc.
$45
BeiGene USA, Inc.
$45
MorphoSys, US Inc.
$39
SOBI, INC
$33
ABBVIE INC.
$33
SUN PHARMACEUTICAL INDUSTRIES INC.
$32
PUMA BIOTECHNOLOGY, INC.
$28
Stemline Therapeutics Inc.
$28
Blueprint Medicines Corporation
$26
PharmaEssentia USA Corporation
$23
Kite Pharma, Inc.
$23
Janssen Pharmaceuticals, Inc
$22
Deciphera Pharmaceuticals Inc.
$22
SERVIER PHARMACEUTICALS LLC
$21
GENZYME CORPORATION
$20
Merck Sharp & Dohme LLC
$19
Astellas Pharma US Inc
$19
Cumberland Pharmaceuticals, Inc.
$17
Chiesi USA, Inc.
$16
Amgen Inc.
$14
Top 3 companies account for 35.6% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$2,160
Janssen Biotech, Inc.
$848
AstraZeneca Pharmaceuticals LP
$842
E.R. Squibb & Sons, L.L.C.
$774
Celgene Corporation
$634
Astellas Pharma US Inc
$565
Eisai Inc.
$456
Incyte Corporation
$440
Seagen Inc.
$377
Takeda Pharmaceuticals U.S.A., Inc.
$361
Regeneron Healthcare Solutions, Inc.
$350
PharmaEssentia USA Corporation
$323
Gilead Sciences, Inc.
$322
BeiGene USA, Inc.
$320
PFIZER INC.
$292
Amgen Inc.
$286
NOVARTIS PHARMACEUTICALS CORPORATION
$283
Karyopharm Therapeutics Inc.
$267
Daiichi Sankyo Inc.
$254
GENZYME CORPORATION
$223
CSL Behring
$214
Genentech USA, Inc.
$199
PUMA BIOTECHNOLOGY, INC.
$194
GlaxoSmithKline, LLC.
$168
Kite Pharma, Inc.
$146
Ipsen Biopharmaceuticals, Inc
$145
Stemline Therapeutics Inc.
$127
Sobi, Inc
$118
Neurelis, Inc.
$117
Dendreon Pharmaceuticals LLC
$114
Pharmacyclics LLC, an AbbVie Company
$109
Seattle Genetics, Inc.
$109
Foundation Medicine, Inc.
$105
Merck Sharp & Dohme LLC
$104
EISAI INC.
$101
Blueprint Medicines Corporation
$73
Lilly USA, LLC
$72
ARRAY BIOPHARMA INC
$71
Agios Pharmaceuticals, Inc.
$70
Alexion Pharmaceuticals, Inc.
$67
AVEO Pharmaceuticals, Inc.
$66
Taiho Oncology, Inc.
$63
MorphoSys, US Inc.
$62
CTI BioPharma Corp.
$60
ABBVIE INC.
$59
Tempus AI, Inc
$58
SANOFI-AVENTIS U.S. LLC
$55
Bayer Healthcare Pharmaceuticals Inc.
$53
SOBI, INC
$51
TOLMAR Pharmaceuticals, Inc.
$51
Pharmacosmos Therapeutics Inc.
$49
Adaptive Biotechnologies Corporation
$49
Deciphera Pharmaceuticals Inc.
$48
Rigel Pharmaceuticals, Inc.
$48
SECURA BIO, INC.
$47
SERVIER PHARMACEUTICALS LLC
$44
Emmaus Medical, Inc.
$35
SUN PHARMACEUTICAL INDUSTRIES INC.
$32
TAIHO ONCOLOGY, INC.
$31
Sun Pharmaceutical Industries Inc.
$29
Progenics Pharmaceuticals, Inc.
$29
Pharmacyclics LLC, An AbbVie Company
$29
TerSera Therapeutics LLC
$28
AbbVie Inc.
$27
Alnylam Pharmaceuticals Inc.
$26
ImmunoGen, Inc.
$25
EUSA Pharma (US) LLC
$25
Puma Biotechnology, Inc.
$24
Spectrum Pharmaceuticals Inc.
$22
Epizyme, Inc.,
$22
Janssen Pharmaceuticals, Inc
$22
RECORDATI_RARE_DISEASES_INC.
$21
Exelixis Inc.
$21
Kyowa Kirin, Inc.
$19
Mirati Therapeutics, Inc.
$18
Bayer HealthCare Pharmaceuticals Inc.
$18
Cumberland Pharmaceuticals, Inc.
$17
Acrotech Biopharma Inc.
$17
Chiesi USA, Inc.
$16
Top 3 companies account for 27.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · Afstyla · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRUKINSA · CABLIVI · CALQUENCE · COPIKTRA · COSELA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ERLEADA · EVENITY · Elahere · Endari · Enhertu · FERRIPROX · FOTIVDA · Fabhalta · GAMIFANT · GAVRETO · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Idelvion · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Odomzo · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · PYLARIFY · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · Revlimid · Rezlidhia · SANCUSO · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SYLVANT · SYNAGIS · Stivarga · Sylvant · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tazverik · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · VALTOCO · VENCLEXTA · VERZENIO · Venclexta · Vonjo · XALKORI · XGEVA · XPOVIO · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
116
Per 100K population
3.5
County median income
$102,285
Nearest hospital
SHARP CHULA VISTA MEDICAL CENTER
2.2 mi
2.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Schwerkoske is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Schwerkoske experienced with anti-nausea injection (ondansetron/zofran)?
Based on Medicare claims data, Dr. Schwerkoske performed 714 anti-nausea injection (ondansetron/zofran) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Schwerkoske receive payments from pharmaceutical companies?
Yes. Dr. Schwerkoske received a total of $14,219 from 79 companies across 521 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Schwerkoske's costs compare to other hematology & oncology specialists in Chula Vista?
Dr. Schwerkoske's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Schwerkoske) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Chula Vista
Browse hematology & oncology specialists in Chula Vista ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology